Following Dupixent’s rise, Sanofi heads downstream in immunology for $125M small molecule pact with Recludix
As Sanofi expands the reach of its blockbuster Dupixent, the French Big Pharma is looking to go further downstream in the IL-13 and IL-4 space with more inflammation and immunology drugs. It’s doling out $125 million in upfront payments to Recludix Pharma to do so.
This is Sanofi’s second preclinical collaboration of the week, following a sickle cell disease tie-up with Scribe Therapeutics. It will work with San Diego-based Recludix on inhibitors of STAT6, a transcription factor that hits the activity of key cytokines driving type 2 inflammatory diseases — namely IL-13 and IL-4, which are targeted by Sanofi and Regeneron’s Dupixent.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.